ACELYRIN, Inc.

Delisted

CIK 1962918fmd_1AXDBQNANZJFKBGJ33TBVKNGHAManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2021 to Mar 31, 2025, 14 periods

Income Statement · Annual · Millions · USD
Line item	FY2021	FY2022	FY2023	FY2024
Research and development	38	56	356	238
Total operating expenses	42	69	422	316
Operating income	(42)	(69)	(422)	(316)
Interest and investment income	0	4	31	31
Other non-operating income (expense)	(0)	(0)	(0)	37
Income tax expense	–	0	0	0
Net income	(42)	(65)	(382)	(248)